{
  "id": 14109356,
  "title": "Anaptysbio director Renton Hollings sells $249,371 of shares",
  "url": "https://urgent.news/2026/10/13/anaptysbio-director-renton-hollings-sells-249-371-of-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-13T03:31:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/anaptysbio-director-renton-hollings-sells-249371-of-shares-93CH-4945355"
  },
  "original_language": "en",
  "account": "Renton Hollings, a director at AnaptysBio (NASDAQ:ANAB), sold 5,000 shares of the company's common stock on October 1, 2026, for a total of $249,371. The shares were traded at prices between $49.435 and $50.37 per share, with an average price of $49.8743. The sale was made under a pre-established Rule 10b5-1 trading plan, which Hollings established on March 30, 2026. The transaction occurred as AnaptysBio shares have shown a 113% return over the past year, currently trading at $46.04, which is below Hollings' sale price. InvestingPro analysis indicates that ANAB is undervalued, with a Fair Value of $55.86, making it a potential opportunity on their list of undervalued stocks. On the same day, Hollings exercised options to buy 5,000 shares at an exercise price of $18.03 per share, totaling $90,150. This brought his direct ownership to 10,995 shares, in addition to options to purchase 102,320 shares. AnaptysBio has been the focus of analyst assessments and regulatory matters, including legal proceedings between the company and GSK regarding contractual obligations for the drug Jemperli. Wolfe Research has given AnaptysBio an Outperform rating with a price target of $78, while TD Cowen reduced its target to $70 on a Buy rating due to regulatory developments concerning a partner company's drug application.",
  "summary": null,
  "key_points": [
    "Renton Hollings sold 5,000 ANAB shares for $249,371 on 1 October 2026",
    "Sale under Rule 10b5-1 plan, shares traded $49.435-$50.37 per share",
    "ANAB shares up 113% year-to-date, currently $46.04 below sale price"
  ],
  "editors_take": "Executing trades through a pre-established Rule 10b5-1 plan allows company leadership to liquidate significant holdings while maintaining a substantial long-term stake through the simultaneous exercise of stock options.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}